{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:11:40Z","timestamp":1789053100105,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10620-026-10003-x","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:29:12Z","timestamp":1781692152000},"page":"5219-5227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selecting Pharmacologic Interventions for MASH"],"prefix":"10.1007","volume":"71","author":[{"given":"Jason J.","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Horwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"10003_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"Z Younossi","year":"2016","unstructured":"Younossi Z, Koenig AB, Abdelatif D et al. Global Epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology."},{"key":"10003_CR2","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u20131835.","journal-title":"Hepatology."},{"key":"10003_CR3","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385:1559\u20131569.","journal-title":"N Engl J Med."},{"key":"10003_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u20131565.","journal-title":"Hepatology."},{"key":"10003_CR5","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e168-185.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"10003_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jhep.2025.05.013","volume":"83","author":"P Ochoa-Allemant","year":"2025","unstructured":"Ochoa-Allemant P, Hubbard RA, Kaplan DE et al. Cause-specific mortality in patients with steatotic liver disease in the United States. J Hepatol. 2025;83:860\u2013869.","journal-title":"J Hepatol."},{"key":"10003_CR7","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69:2672\u20132682.","journal-title":"Hepatology."},{"key":"10003_CR8","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81: 492\u2013542"},{"key":"10003_CR9","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u20131556.","journal-title":"J Hepatol."},{"key":"10003_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.metabol.2012.08.005","volume":"62","author":"ZM Younossi","year":"2013","unstructured":"Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism. 2013;62:352\u2013360.","journal-title":"Metabolism."},{"key":"10003_CR11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.14309\/ajg.0000000000002519","volume":"119","author":"M Camilleri","year":"2023","unstructured":"Camilleri M, Lupianez-Merly C. Effects of GLP-1 and Other Gut Hormone Receptors on the Gastrointestinal Tract and Implications in Clinical Practice. Am J Gastroenterol. 2023;119:1028\u20131037.","journal-title":"Am J Gastroenterol."},{"key":"10003_CR12","doi-asserted-by":"publisher","first-page":"e1697","DOI":"10.1210\/clinem\/dgae119","volume":"109","author":"R Eriksen","year":"2024","unstructured":"Eriksen R, White MC, Dawed AY et al. The Association of Cardiometabolic, Diet and Lifestyle Parameters With Plasma Glucagon-like Peptide-1: An IMI DIRECT Study. J Clin Endocrinol Metab. 2024;109:e1697\u2013e1707.","journal-title":"J Clin Endocrinol Metab."},{"key":"10003_CR13","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1210\/clinem\/dgad072","volume":"108","author":"L Li","year":"2023","unstructured":"Li L, Song Y, Shi Y et al. Thyroid Hormone Receptor-\u03b2 Agonists in NAFLD Therapy: Possibilities and Challenges. J Clin Endocrinol Metab. 2023;108:1602\u20131613.","journal-title":"J Clin Endocrinol Metab."},{"key":"10003_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390:497\u2013509.","journal-title":"N Engl J Med."},{"key":"10003_CR15","doi-asserted-by":"publisher","first-page":"s9","DOI":"10.1016\/S0168-8278(25)00311-3","volume":"82","author":"N Alkhouri","year":"2025","unstructured":"Alkhouri N, Taub R, Lu X et al. LBO-002 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension in 122 patients with compensated MASH cirrhosis. J Hepatol. 2025;82:s9-10.","journal-title":"J Hepatol."},{"key":"10003_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000670","volume":"9","author":"N Ravela","year":"2025","unstructured":"Ravela N, Shackelford P, Blessing N et al. Early experience with resmetirom to treat metabolic dysfunction-associated steatohepatitis with fibrosis in a real-world setting. Hepatol Commun. 2025;9:e0670.","journal-title":"Hepatol Commun."},{"key":"10003_CR17","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728\u2013742.","journal-title":"Nat Rev Endocrinol."},{"key":"10003_CR18","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392:2089\u20132099.","journal-title":"N Engl J Med."},{"key":"10003_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.23276","volume":"51","author":"K Promrat","year":"2010","unstructured":"Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121\u2013129.","journal-title":"Hepatology."},{"key":"10003_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367\u2013378.","journal-title":"Gastroenterology."},{"key":"10003_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med."},{"key":"10003_CR22","unstructured":"Newsome PN, Armstrong MJ, Bakulin I, et al. Weight-independent benefits of Semaglutide on histology and non-invasive tests in participants with biopsy-defined MASH: Post hoc analysis of the ESSENCE trial part 1. In: Proceedings and abstracts of the European Congress on Obesity, May 11\u201314, 2025, Malaga, Spain: European Congress on Obesity, 2025."},{"key":"10003_CR23","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","volume":"31","author":"M Jara","year":"2025","unstructured":"Jara M, Norlin J, Kjaer MS et al. Modulation of metabolic, inflammatory, and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med. 2025;31:3128\u20133140.","journal-title":"Nat Med."},{"key":"10003_CR24","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Kirstine B-F, Colhoun HM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221\u20132232.","journal-title":"N Engl J Med."},{"key":"10003_CR25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/hep4.1689","volume":"5","author":"AS Barritt","year":"2021","unstructured":"Barritt AS, Watkins S, Gitlin N et al. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study. Hepatol Commun. 2021;5:938\u2013946.","journal-title":"Hepatol Commun."},{"key":"10003_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","volume":"81","author":"VL Chen","year":"2025","unstructured":"Chen VL, Morgan TR, Rotman Y et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025;81:312\u2013320.","journal-title":"Hepatology."},{"key":"10003_CR27","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","volume":"22","author":"M Noureddin","year":"2024","unstructured":"Noureddin M, Charlton MR, Harrison SA et al. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH\/NASH and Moderate to Noncirrhotic Advanced Fibrosis. Clin Gastroenterol Hepatol. 2024;22:2367\u20132377.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10003_CR28","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"LB Knudsen","year":"2010","unstructured":"Knudsen LB, Madsen LW, Andersen S et al. Glucagon-like Peptide-1 receptor agonists activate srodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473\u20131486.","journal-title":"Endocrinology."},{"key":"10003_CR29","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, Zinman B, Hemmingsson JU et al. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016;39:1702\u20131710.","journal-title":"Diabetes Care."},{"key":"10003_CR30","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41591-024-03463-z","volume":"31","author":"MR Pasqua","year":"2025","unstructured":"Pasqua MR, Tsoukas MA, Kobayati A et al. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nat Med. 2025;31:1239\u20131245.","journal-title":"Nat Med."},{"key":"10003_CR31","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834\u20131844.","journal-title":"N Engl J Med."},{"key":"10003_CR32","unstructured":"Noureddin M, Rinella M, Taub R, et al. Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or \u22655% Weight Loss and\/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study. In: Proceedings and abstracts of The Liver Meeting, 15\u201319, 2024, San Diego, United States: The Liver Meeting, 2024."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10003-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10003-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10003-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:03:13Z","timestamp":1789052593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10003-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10003"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10003-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJP, BHH, MC have no relevant financial disclosures to report. Author JAG is a shareholder of Novo Nordisk, shareholder of Viking, consultant and speaker for Madrigal, consultant and shareholder for Altimmune Inc, speaker for AbbVie, speaker for Gilead Sciences, and speaker for Ipsen. Author SS is a speaker for the following companies: AbbVie, Gilead Sciences, Novo Nordisk, Salix, Takeda, Mallinckrodt Pharmaceuticals, Madrigal, Ipsen, Eisai, Sequana. Author SS is a consultant for the following companies: Gilead Sciences, Mallinckrodt Pharmaceuticals, Madrigal, Ipsen, Sequana.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}